Transdermal acrylic multipolymer drug delivery system
Patent 4994267 Issued on February 19, 1991. Estimated Expiration Date: 
January 11, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
January 11, 2009. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesSkin permeation enhancer compositions Device for the administration of an active agent to the skin or mucosa Estradiol transdermal delivery system Patent #: 4906475 InventorAssigneeApplicationNo. 295847 filed on 01/11/1989US Classes:514/182, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system424/418, Protein or derivative or polysaccharide or derivative424/449, Transdermal or percutaneous424/484, Matrices424/485, Natural gums, resin or latex424/486, Synthetic polymer514/509, (O=)N(=O)-O-C containing (e.g., nitrate ester, etc.)514/772.4Polymer from ethylenic monomers onlyExaminersPrimary: Cashion, Merrell C. Jr.Assistant: Jones, Leonidas J. Attorney, Agent or FirmInternational ClassA61K 031/74AbstractA dermal composition comprising a drug, a multipolymer of ethylene-vinyl acetate, an acrylic polymer, and optionally one or more monomers, a natural or synthetic rubber and a tackifying agent. The ratio of the multipolymer to the rubber is, respectively, about 1:1 to about 10:1 and more preferably, 1:1 to 5:1 and more preferably 3:1. The dermal composition can optionally contain a crosslinking agent, tackifiers, penetration enhancers and other ingredients known for use in adhesives for the transdermal delivery of drugs. The dermal compositions can be produced by a variety of methods known in the preparation of drug containing adhesive preparations including the homogenous mixing of the multipolymer, drug and optional crosslinking agent and additional ingredients in solution or suspension or emulsion followed by removal of excess solvent. | |
